Aruni Ghose

Aruni Ghose: AKT + Androgen Receptor Signalling Inhibitors in the mCRPC

Aruni Ghose, Internal Medicine Resident at Barts Health NHS Trust, shared a post on LinkedIn:

“Hot off the Press from my Evidence Generation Collaborations – We did a Meta Analysis of 6 Randomised Controlled Trials of Combination AKT + Androgen Receptor Signalling Inhibitors in the Metastatic Castrate Resistant Prostate Cancer Setting.

Noted a 16 percent reduction in radiographic progression in favour of combination with a modest Overall Survival increase.

Tulika Nahar from Queen’s University Belfast with the National Medical Research Association (NMRA) led this strong evidence work.

With Maria Anna Bantounou from University of Aberdeen, Isabella Savin from Imperial College London and Nakul Chohan from Lancaster University – Loved the diversity and their drive!!

Published by Elsevier Oncology in Clinical Genitourinary Cancer.

Efficacy and Safety of Combination AKT and Androgen Receptor Signaling Inhibition in Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis

Authors: Tulika A K Nahar, Maria Anna Bantounou, Isabella Savin, Nakul Chohan, Niraj S Kumar, Aruni Ghose, Ian J McEwan.”

Aruni Ghose: AKT + Androgen Receptor Signalling Inhibitors in the mCRPC

AKT androgen receptor signaling inhibitors Aruni Ghose cancer Clinical Genitourinary Cancer Elsevier Oncology Ian J McEwan Imperial College London Isabella Savin Lancaster University Maria Anna Bantounou metastatic castrate-resistant prostate cancer (mCRPC) Nakul Chohan National Medical Research Association Niraj S Kumar OncoDaily Oncology Queen's University Belfast Tulika A K Nahar University of Aberdeen